Evidence-based treatment recommendations for uremic bleeding
- PMID: 17322926
- DOI: 10.1038/ncpneph0421
Evidence-based treatment recommendations for uremic bleeding
Abstract
Uremic bleeding syndrome is a recognized consequence of renal failure and can result in clinically significant sequelae. Although the pathophysiology of the condition has yet to be fully elucidated, it is believed to be multifactorial. This article is a review of both the normal hemostatic and homeostatic mechanisms that operate within the body to prevent unnecessary bleeding, as well as an in-depth discussion of the dysfunctional components that contribute to the complications associated with uremic bleeding syndrome. As a result of the multifactorial nature of this syndrome, prevention and treatment options can include one or a combination of the following: dialysis, erythropoietin, cryoprecipitate, desmopressin, and conjugated estrogens. Here, these treatment options are compared with regard to their mechanism of action, and onset and duration of efficacy. An extensive review of the clinical trials that have evaluated each treatment is also presented. Lastly, we have created an evidence-based treatment algorithm to help guide clinicians through most clinical scenarios, and answered common questions related to the management of uremic bleeding.
Comment in
-
Tranexamic acid and uremic bleeding: evidence-based treatment recommendations.Nat Clin Pract Nephrol. 2007 Jun;3(6):E2; author reply E3. doi: 10.1038/ncpneph0528. Nat Clin Pract Nephrol. 2007. PMID: 17525710 No abstract available.
Similar articles
-
Management of uremic bleeding.Clin Pharm. 1990 Sep;9(9):673-81. Clin Pharm. 1990. PMID: 2171866 Review.
-
Conjugated estrogens for the management of bleeding associated with renal failure.N Engl J Med. 1986 Sep 18;315(12):731-5. doi: 10.1056/NEJM198609183151204. N Engl J Med. 1986. PMID: 3018561 Clinical Trial.
-
Variability in response to cryoprecipitate treatment for hemostatic defects in uremia.Yale J Biol Med. 1990 Jan-Feb;63(1):1-7. Yale J Biol Med. 1990. PMID: 2113328 Free PMC article.
-
Bleeding disorders in uremia: pathophysiology and treatment.Adv Nephrol Necker Hosp. 1989;18:171-86. Adv Nephrol Necker Hosp. 1989. PMID: 2493714 Review.
-
Therapeutic manipulations in uremic bleeding.J Clin Pharmacol. 1985 Jul-Aug;25(5):315-7. doi: 10.1002/j.1552-4604.1985.tb02848.x. J Clin Pharmacol. 1985. PMID: 3928704 Review. No abstract available.
Cited by
-
Highly sensitive optical biosensor for thrombin based on structure switching aptamer-luminescent silica nanoparticles.J Fluoresc. 2013 Jan;23(1):137-46. doi: 10.1007/s10895-012-1127-0. Epub 2012 Sep 11. J Fluoresc. 2013. PMID: 22965479
-
Platelet Dysfunction Diseases and Conditions: Clinical Implications and Considerations.Adv Ther. 2020 Sep;37(9):3707-3722. doi: 10.1007/s12325-020-01453-4. Epub 2020 Jul 29. Adv Ther. 2020. PMID: 32729008 Review.
-
Clinical Care Pathway and Management of Major Bleeding Associated with Nonvitamin K Antagonist Oral Anticoagulants: A Modified Delphi Consensus from Saudi Arabia and UAE.Mediterr J Hematol Infect Dis. 2024 May 1;16(1):e2024038. doi: 10.4084/MJHID.2024.038. eCollection 2024. Mediterr J Hematol Infect Dis. 2024. PMID: 38882457 Free PMC article. Review.
-
Carbamylation is Instrumental in End-Stage Kidney Disease Coagulopathies: The Impact on von Willebrand Factor and Platelet Functionality.Thromb Haemost. 2025 Mar;125(3):230-240. doi: 10.1055/a-2373-3792. Epub 2024 Jul 25. Thromb Haemost. 2025. PMID: 39053581 Free PMC article.
-
Spontaneous hemocholecyst in an end-stage renal failure patient on low molecular weight heparin hemodialysis.Case Rep Surg. 2012;2012:363924. doi: 10.1155/2012/363924. Epub 2012 Dec 11. Case Rep Surg. 2012. PMID: 23304616 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials